



The

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701-3271
WWW.FULBRIGHT.COM

STEVEN L. HIGHLANDER PARTNER SHIGHLANDER@FULBRIGHT.COM DIRECT DIAL:

(512) 536-3184

TELEPHONE: FACSIMILE:

(512) 474-5201 (512) 536-4598

February 7, 2005

CERTIFICATE OF MAILING 37 C.F.R 1.8

I certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

February 7, 2005

Date

Steven L. Highlander

MS AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

RE:

U.S. Patent Application No. 10/693,258 entitled "GB VIRUS C AND METHODS OF

TREATING VIRAL INFECTIONS" - Jack T. Stapleton et al.

Our reference: IOWA:059US Client reference: UIRF3021

Sir:

Enclosed for filing in the above-referenced patent application is a Supplemental Information Disclosure Statement, Form PTO-1449, and references A1-A11 and C1-C60.

No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/IOWA:059US.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,

Steven L. Highlander

Reg. No. 37,642

SLH/kvp

Encl.: as noted

25498104.1





#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Jack T. Stapleton et al.

Serial No.: 10/693,258

Filed: October 24, 2003

For: GB VIRUS C AND METHODS OF TREATING VIRAL INFECTIONS

Group Art Unit: 1653

Examiner: Unknown

Atty. Dkt. No.: IOWA:059US

CERTIFICATE OF MAILING 37 C.F.R 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to:, MS AMENDMENT, Commissioner for Patents, P.O. Box 1,50, Alexandria, VA 22313-1450, on the pate below:

February 7, 2005

Date

Highlander

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

MS AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R §§ 1.97(g), (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be

conclued to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Supplemental Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R § 1.97(b). No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/IOWA:059US.

Applicant respectfully requests that the listed documents be made of record in the present case.

Respectfully submitted,

Steven L. Highlander

Reg. No. 37,259

Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P. 600 Congress Avenue, Suite 2400 Austin, Texas 78701 (512) 474-5201

Date: Febru

February 7, 2005

PTO-1449 (modified)

f Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No. IOWA:059US

Serial No. 10/693,258

**Applicant** 

Jack T. Stapleton et al.

Filing Date: October 24, 2003 Group: 1653

**U.S. Patent Documents** See Page 1

**Foreign Patent Documents** See Page 1

Other Art See Page 1

### **U.S. Patent Documents**

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	5,620,896	4/15/97	Herrmann, et al.	435	320.1	4/20/95
	A2	5,766,840	6/16/98	Kim et al.	435	5	6/5/95
	A3	5,766,916	6/16/98	Belyaev et al.	435	219	4/24/96
	A4	5,824,507	10/20/98	Kim et al.	435	69.3	5/19/95
	A5	5,849,532	12/15/98	Kim et al.	435	69.3	6/6/95
	A6	5,856,134	1/5/99	Kim et al.	435	69.3	6/5/95
	A7	5,859,230	1/12/99	Kim et al.	536	24.33	3/6/96
	A8	5,874,563	2/23/99	Kim, et al.	536	23.72	6/5/95
	A9	5,958,895	9/28/99	Pachuk, et al.	514	44	10/23/97
	A10	6,004,799	12/21/99	Luciw, et al.	435	236	12/21/99
	A11	6,156,495	12/05/00	Pilot-Matias et al.	435	5	4/19/96

### **Foreign Patent Documents**

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation			
	C1	Agnello, et al., "Hepatitis C virus and other Flaviviridae viruses enter cells via low density lipoprotein receptor," PNAS, 96(22):12766-12771, 1999.			
	C2	Akiyoshi, et al., "Intraspousal Transmission of GB Virus C/Hepatitis G Virus in an Hepatitis C Virus Hyperendemic Area in Japan," Am. J. Gastroenterol., 94(6):1627-1631, 1999.			
	C3	Alter, et al., "Acute non-A-E Hepatitis in the United States and the Role of Hepatitis G Virus Infection," N. Engl. J. Med., 336(11):741-746. 1997.			

25498059.1

**EXAMINER:** 

**DATE CONSIDERED:** 

Form PTO-1449 (modified)		Atty. Docket No. Serial No. 10WA:059US 10/693,258		
List of Patents and Publications for	Applicant's	Applicant  Jack T. Stapleton <i>et al.</i>		
INFORMATION DISCLOSURE ST	TATEMENT			
(Use several sheets if necessary)		Filing Date: October 24, 2003	Group: 1653	
U.S. Patent Documents Foreign P		Patent Documents	Other Art	
See Page 1		ee Page 1	See Page 1	

Other Art	(Including	Author,	Title,	Date	<b>Pertinent</b>	Pages,	Etc.)
-----------	------------	---------	--------	------	------------------	--------	-------

Exam. Init.	Ref. Des.	Citation
	C4	Alter, et al., "The Incidence of Transfusion-Associated Hepatitis G Virus Infection and Its Relation to Liver Disease," N. Engl. J. Med., 336(11):747-754. 1997.
	C5	Asada, et al., "Human Herpesvirus 6 Infects Dendritic Cells and Suppresses Human Immunodeficiency Virus Type 1 Replication in Coinfected Cultures," J. Virol. 73(5):4019-4028, 1999.
	C6	Beard, et al., "An Infectious Molecular Clone of a Japanese Genotype 1b Hepatitis C Virus," Hepatology, 30(1):316-324, 1999.
	C7	Birkenmeyer, et al., "Isolation of a GB Virus-Related Genome From a Chimpanzee," J. Med. Virol., 56:44-51, 1998.
-	C8	Bukh, et al., "Experimental Infection of Chimpanzees with Hepatitis G Virus and Genetic Analysis of the Virus," J. Inf. Dis., 177:855-862, 1998.
	C9	Bukh, et al., "Toward a Surrogate Model for Hepatitis C Virus: An Infectious Molecular Clone of the GB Virus-B Hepatitis Agent," Virol., 262:470-478, 1999.
	C10	Cohen, et al., "Hepatitis A Virus cDNA and Its RNA Transcripts Are Infectious in Cell Culture," J. Virol., 61(10):3035-3039, 1987.
	C11	Dawson, et al., "Prevalence Studies of GB Virus-C Infection Using Reverse Transcriptase-Polymerase Chain Reaction," J. Med. Virol., 50:97-103, 1996.
	C12	de Martino, et al., "Hepatitis G Virus Infection in Human Immunodeficiency Virus Type 1-Infected Mothers and Their Children," J. Infect. Dis., 178:862-865, 1998.
	C13	Deacon, et al., "Genomic Structures of an Attenuated Quasi Species of HIV-1 from a Blood Transfusion Donor and Recipients," Science, 270:988-991, 1995.
	C14	Dickens, et al., "GB Virus C, Hepatitis G Virus, or Human Orphan Flavivirus?" Hepatology, 25(5):1285-1286, 1997.
	C15	Easterbrook, "Long-term Non-Progression in HIV Infection: Definitions and Epidemiological Issues," <i>J.Infect</i> ,. 38:71-73, 1999.
	C16	Elvander, et al., "An Experimental Study of a Concurrent Primary Infection with Bovine Respiratory Syncytial Virus (BRSV) and Bovine Viral Diarrhoea Virus (BVDV) in Calves," Acta. Vet. Scand, 39:251-264, 1998.

25498059.1

EXAMINER: DATE CONSIDERED:

Form PTO-1449 (modified)		. Docket No.	Serial No.	
, ,		IOWA:059US 10/693,258		
List of Patents and Publications for A	applicant's App	Applicant		
	Jack	T. Stapleton et al.		
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				
		ng Date: ober 24, 2003	Group: 1653	
U.S. Patent Documents Foreign		Documents	Other Art	
See Page 1 S		See Page 1 See Page 1		

Exam. Init.	Ref. Des.	Citation
	C17	Emerson, et al., "cDNA Clone of Hepatitis A Virus Encoding a Virulent Virus: Induction of Viral Hepatitis by Direct Nucleic Acid Transfection of Marmosets," J. Virol., 66(11):6649-6654, 1992.
	C18	Feucht, et al., "Distribution of Hepatitis G Viremia and Antibody Response to Recombinant Proteins With Special Regard to Risk Factors in 709 Patients," Hepatology, 26(2):491-494, 1997.
	C19	Fogeda, et al.,. In Vitro Infection of Human Peripheral Blood Mononuclear Cells by GB Virus C/Hepatitis G Virus," J. Virol. 73(5):4052-4061, 1999.
	C20	Gale, Jr,. et al., "Control of PKR Protein Kinase by Hepatitis C Virus Nonstructural 5A Protein: Molecular Mechanisms of Kinase Regulation," Mol. Cell. Biol. 18(9):5208-5218, 1998
	C21	Gutierrez, et al., "Seroprevalence of GB Virus C and Persistence of RNA and Antibody," J. Med. Virol., 53:167-173, 1997.
	C22	Hong, et al., "Generation of Transmissible Hepatitis C Virions from a Molecular Clone in Chimpanzees," Virology, 256:36-44, 1999.
	C23	Huang, et al., "The role of a mutant CCR5 allele in HIV-1 transmisssion and disease progression," Nature Med., 2:1240-1243, 1996.
	C24	Kolykhalov, et al., "Identification of a Highly Conserved Sequence Element at the 3' Terminus of Hepatitis C Virus Genome RNA," J. Virol., 70(6):3363-3371, 1996.
	C25	Kolykhalov, et al., "Transmission of Hepatitis C by Intrahepatic Inoculation with Transcribed RNA," Science, 277:570-574, 1997.
	C26	Laskus, et al., "Detection of Hepatitis G Virus Replication Sites by Using Highly Strand-Specific Tth-Based Reverse Transcriptase PCR," J. Virol., 72(4):3072-3075, 1998.
	C27	Leary, et al., "Sequence and Genomic Organization of GBV-C: A Novel Member of the Flaviviridae Associated With Human Non-A-E Hepatitis," J. Med. Virol., 48:60-67, 1996.
	C28	Lefrère, et al., "Carriage of GB Virus C/Hepatitis G Virus RNA Is Associated with a Slower Immunologic, Virologic, and Clinical Progression of Human Immunodeficiency Virus Disease in Coinfected Persons," J. Infect. Dis., 179:783-789, 1999.
,	C29	Linnen, et al., "Molecular Cloning and Disease Association of Hepatitis G Virus: A Transfusion-Transmissible Agent," Science, 271:505-508, 1996.

25498059.1

EXAMINER: DATE CONSIDERED:

Form PTO-1449 (modified)		Atty. Docket No. Serial No. 10/693,258	
List of Patents and Publications for	Applicant's	Applicant  Jack T. Stapleton <i>et al.</i>	
INFORMATION DISCLOSURE STATEMENT			
(Use several sheets if necessa	ry)	Filing Date: October 24, 2003	Group: 1653
U.S. Patent Documents Foreign I		Patent Documents	Other Art
See Page 1 Se		See Page 1	See Page 1

Exam. Init.	Ref. Des.	Citation
	C30	Melvin, et al., "Biophysical characterization of GB virus C from human plasma," J. Virol. Methods, 71:147-157, 1998.
	C31	Nerurkar, et al., "High Prevalence of GB Virus C/Hepatitis G Virus Infection Among Homosexual Men Infected With Human Immunodeficiency Virus Type 1: Evidence for Sexual Transmission," J. Med. Virol., 56:123-127, 1998.
	C32	Okamoto, et al., "The entire nucleotide sequences of two GB virus C/hepatitis G virus isolates of distinct genotypes from Japan," J. Gen. Virol., 78:737-745. 1997.
	C33	Pang et al., "Development of dengue virus replicons expressing HIV-1 gp120 and other heterologous genes: a potential future tool for dual vaccination against dengue virus and HIV," BMC Microbiology, 1(28):1-9, 2001.
	C34	Pessoa, et al., "Quantitation of Hepatitis G and C Viruses in the Liver: Evidence That Hepatitis G Virus Is Not Hepatotropic," Hepatol., 27(3):877-880, 1998.
	C35	Pinto, et al., "Inhibition of Human Immunodeficiency Virus Type 1 Replication prior to Reverse Transcription by Influenza Virus Stimulation," J. Virol. 74(10):4505-4511, 2000.
	C36	Rinaldo, Jr. et al., "Fetal and Adult Bovine Interferon Production During Bovine Viral Diarrhea Virus Infection," <i>Infect.Immun.</i> 14(3):660-666, 1976.
	C37	Robertson, et al., "Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization," Arch. Virol., 143(12):2493-2503, 1998.
	C38	Rowland-Jones, "Long-term Non-progression in HIV Infection: Clinico pathological Issues," <i>J.Infect.</i> , 38:67-70, 1999.
	C39	Sabin, et al., "Effect of Coinfection With Hepatitis G Virus on HIV Disease Progression in Hemophilic Men," J. Acquir. Immune Defic. Syndr., 19:546-547, 1998.
	C40	Schmidt, et al., "Direct Detection of Hepatitis C Virus (HCV) RNA From Whole Blood, and Comparison With HCV RNA in Plasma and Peripheral Blood Monouclear Cells," J. Med. Virol., 47:153-160, 1995.
	C41	Seipp, et al., "Hepatotropism of GB virus C (GBV-C): GBV-C replication in human hepatocytes and cells of human hepatoma cell lines," J. Hepatol., 30:570-579, 1999.

25498059.1

EXAMINER:	DATE CONSIDERED:

Form PTO-1449 (modified)		Atty. Docket No. Serial No. 10WA:059US 10/693,258		
List of Patents and Publications for	· Applicant's	Applicant  Jack T. Stapleton <i>et al.</i>		
INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)				
		Filing Date: October 24, 2003	Group: 1653	
U.S. Patent Documents See Page 1	1	Patent Documents See Page 1	Other Art See Page 1	

Exam. Init.	Ref. Des.	Citation
	C42	Shimizu, "Replication of GB Virus C (Hepatitis G Virus) in Interferon-Resistant Daudi Cells," J. Virol., 73(10):8411-8414, 1999.
	C43	Simons, et al., "Identification of two flavivirus-like genomes in the GB hepatitis agent," Proc.Natl.Acad.Sci.USA 92:34013405, 1995.
,	C44	Simons, et al., "Isolation of novel virus-like sequences associated with human hepatitis," Nature Med., 1(6):564-569, 1995.
	C45	Simons, et al., "Translation Initiation in GB Viruses A and C: Evidence for Internal Ribosome Entry and Implications for Genome Organization," J. Virol., 70(9):6126-6135, 1996.
	C46	Stapleton, et al., "Prospective Comparison of Whole-Blood- and Plasma-Based Hepatitis C Virus RNA Detection Systems: Improved Detection Using Whole Blood as the Source of Viral RNA," J. Clin. Microbiol., 37(3):484-489, 1999.
	C47	Tacke, et al., "Humoral Immune Response to the E2 Protein of Hepatitis G Virus Is Associated With Long-Term Recovery From Infection and Reveals a High Frequency of Hepatitis G Virus Exposure Among Healthy Blood Donors," <i>Hepatol.</i> , 26(6):1626-1633, 1997.
	C48	Tanaka, et al., "Acute hepatitis caused by sexual or household transmission of GBV-C," J. Hepatol., 27:1110-1112, 1997.
	C49	Taylor, et al., "Inhibition of the Interferon-Inducible Protein Kinase PKR by HCV E2 Protein," Science, 285:107-110, 1999.
	C50	Thomas, et al., "Association of Antibody to GB Virus C (Hepatitis G Virus) with Viral Clearance and Protection from Reinfection," J.Infect. Dis., 177:539-542, 1998.
	C51	Toyoda, et al., "Comparison of Characteristics Between Patients With GB Virus C/Hepatitis G Virus (GBV-C/HGV) RNA and Those With GBV-C/HGV E2-Antibody in Patients With Hemophilia," J.Med. Virol., 60:34-38, 2000.
	C52	Wu, et al., "Prevalence and Risk Factor Analysis of GBV-C/HGV Infection in Prostitutes," J. Med. Virol., 52:83-85, 1997.
	C53	Wu, et al., "Promoter-Dependent Tissue-Specific Expressive Nature of Imprinting Gene, Insulin-like Growth Factor II, in Human Tissues," Biochem. Biophys. Res. Commun., 233(1):221-6, 1997.

25498059.1

EXAMINER:	DATE CONSIDERED:

Form PTO-1449 (modified)		Atty. Docket No. IOWA:059US	Serial No. 10/693,258
List of Patents and Publications for	Applicant's	Applicant  Jack T. Stapleton <i>et al.</i>	
INFORMATION DISCLOSURE STATEMENT			
(Use several sheets if necessary)		Filing Date: October 24, 2003	Group: 1653
U.S. Patent Documents	Foreign l	Patent Documents	Other Art
See Page 1		See Page 1	See Page 1

Exam. Init.	Ref. Des.	Citation
	C54	Wünschmann & Stapleton, "Fluorescence-Based Quantitative Methods for Detecting Human Immunodeficiency Virus Type 1-Induced Syncytia," <i>J. Clin. Microbiol.</i> , 38(8):3055-3060, 2000.
	C55	Wünschmann, et al., "Characterization of Hepatitis C Virus (HCV) and HCV E2 Interactions with CD81 and the Low-Density Lipoprotein Receptor," J. Virol., 74(21):10055-10062, 2000.
	C56	Xiang, et al., "Characterization of Hepatitis G Virus (GB-C Virus) Particles: Evidence for a Nucleocapsid and Expression of Sequences Upstream of the E1 Protein," J. Virol., 72(4):2738-2744, 1998.
	C57	Xiang, et al., "Full-Length GB Virus C (Hepatitis G Virus) RNA Transcripts Are Infectious in Primary CD4-Positive T Cells," J. Virol., 74(19):9125-9133, 2000.
	C58	Xiang, et al., "Visualization and characterization of GB virus-C particles: evidence for a nucleocapsid," J. Viral Hepat., 6(S1):16-22, 1999.
	C59	Yanagi, et al., "Transcripts from a single full-length cDNA clone of hepatits C virus are infectious when directly transfected into the liver of a chimpanzee," Proc. Nat'l. Acad. Sci., 94:8738-8743, 1997.
	C60	Yanagi, et al., "Transcripts of a Chimeric cDNA Clone of Hepatitis C Virus Genotype 1b Are Infectious in Vivo," Virology, 244:161-172, 1998.

25498059.1

**EXAMINER:** 

**DATE CONSIDERED:**